Alnylam Pharmaceuticals’ IND application for ALN-VSP has been cleared by the FDA to begin enrolling patients in a Phase I trial. ALN-VSP, an RNAi therapeutic for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumors with liver involvement, contains two small interfering RNAs (siRNAs, the molecules that mediate RNAi), formulated in a lipid nanoparticle developed by Tekmira Pharmaceuticals. Preclinical data in mouse tumor model studies have demonstrate...